EpiVax Therapeutics, Inc. specializes in developing next-generation cancer precision immunotherapies. The company leverages over 20 years of experience in T cell immune engineering to create therapies that activate a complete immune response in patients. EpiVax operates in the biotechnology and healthcare market, focusing on personalized cancer vaccines and immunotherapies. Their proprietary immunoinformatics platform, Ancer, identifies immunogenic, private neoantigens for cancer immune therapy. The business model revolves around the development and commercialization of these personalized therapies, targeting cancer patients who require tailored treatment options. Revenue is generated through the sale of these specialized therapies and potential partnerships or licensing agreements with larger pharmaceutical companies. EpiVax's unique approach allows them to go from biopsy to vaccine administration in just four weeks, positioning them favorably in the neoadjuvant treatment setting and improving therapy outcomes.

Keywords: cancer immunotherapy, T cell engineering, personalized vaccines, immunoinformatics, neoantigens, biotechnology, healthcare, precision medicine, neoadjuvant treatment, proprietary platform.